US EditionQ2 EPS Estimates for Gilead Sciences Reduced by Analyst
Summary by tickerreport.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Q2 EPS Estimates for Gilead Sciences Reduced by Analyst
Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Investment analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Gilead Sciences in a research report issued to clients and investors on Monday, July 14th. Leerink Partnrs analyst D. Graybosch now anticipates that the biopharmaceutical company will post earnings per share of $1.91 […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
